Diagnose und Therapie der chronischen Urtikaria


Altrichter S, Zampeli V, Ellrich A, et al. IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy 2020;in press

Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol 2010;20(5):386–90

Bar Oz B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71(8):105–5

Bruno G, Andreozzi, P, Graf, U. Exercise-induced urticaria – angioedema syndrome: A role in gastroesophageal reflux. In: Vena GA, Puddu, P. (Hrsg.), Proceedings of the International Symposium on Urticaria. Publishers Scientif, Bari, 1998;85–9

Bunselmeyer B, Laubach HJ, Schiller M, et al. Incremental build-up food challenge – a new diagnostic approach to evaluate pseudoallergic reactions in chronic urticaria: a pilot study: stepwise food challenge in chronic urticaria. Clin Exp Allergy 2009;39(1):116–26

Casale T, Maurer M, Saini S. Omalizumab reduced symptoms and improved health-related quality of life (HRQoL) in patients with refractory chronic idiopathic / spontaneous urticaria (CIU/CSU) in three randomized, double-blind, placebo-controlled Phase III trials: A post-hoc analysis of percent change from baseline. Allergy 2014;69(Suppl 99):Abstr 1662

EAACI/GA2LEN/EDF/WAO. 6th Consensus conference on the update and revision of the EAACI/GA2LEN/EDF/WAO guideline for urticaria. Berlin, 03.12.2020

Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep Med 2015;2015:368053

Gonzalez-Medina M, Curto-Barredo L, Labrador-Horrillo M, et al. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol 2017;31(5):e245–e6

Grattan CE, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21(6):695–704

Grattan CE, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000;143(2):365–72

Greaves MW. Chronic urticaria. N Engl J Med 1995;332(26):1767–72

Grob JJ, Auquier P, Dreyfus I, et al. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009;64(4):605–12

Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 2016;175(6):1153–65

Gupta S, Khalilieh S, Kantesaria B, et al. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol 2007;63(5):534–40

Haas N, Hermes B, Henz BM. Adhesion molecules and cellular infiltrate: histology of urticaria. J Investig Dermatol Symp Proc 2001;6(2):137–8

Haas N, Schadendorf D, Henz BM. Differential endothelial adhesion molecule expression in early and late whealing reactions. Int Arch Allergy Immunol 1998;115(3):210–4

Hermes B, Prochazka AK, Haas N, et al. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999;103(2 Pt 1):307-14

Ito Y, Satoh T, Takayama K, et al. Basophil recruitment and activation in inflammatory skin diseases. Allergy 2011;66(8):1107–13

Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981;104(4):369-81

Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol 2016;137(2):474–81

Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017;72(4):519-33

Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;346(3): 175–9

Kay AB, Clark P, Maurer M, et al. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol 2015;172(5):1294–302

Kay AB, Ying S, Ardelean E, et al. Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. Clin Exp Allergy 2014a;44(8):1053–60

Kay AB, Ying S, Ardelean E, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial wheals with low-level persistence in uninvolved skin. Br J Dermatol 2014b;171(3):505–11

Kocaturk E, Maurer M, Metz M, et al. Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy 2017;7:1

Konstantinou GN, Konstantinou GN. Psychological stress and chronic urticaria: A neuro-immuno-cutaneous crosstalk. A systematic review of the existing evidence. Clin Ther 2020; 10.1016/j.clinthera.2020.03.010

Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol 2015;136(2):245–51

Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. J Allergy Clin Immunol Pract 2018;6(2):586-99

Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004;9(2):169–80

Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016;71(6):780–802

Mathelier-Fusade P. Drug-induced urticarias. Clin Rev Allergy Immunol 2006;30(1):19–23

Mathias SD, Crosby RD, Zazzali JL, et al. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2012;108(1):20–4

Maurer M, Abuzakouk M, Berard F, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy 2017a;10.1111/all.13209

Maurer M, Houghton K, Guillet G, et al. Quality of life and presence of angioedema among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. 26. EADV Congress, Genf, Schweiz, 16.September 2017b

Maurer M, Magerl M, Metz M, et al. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy 2013;68(6):816–9

Maurer M, Metz M, Magerl M. Neues zur Pathogenese der chronischen spontanen Urtikaria. Ärztliches Journal Dermatologie 2 2018

Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol 2017c; 10.1016/j. jaci.2017.06.032

Maurer M, Raap U, Staubach P,et al. Real-world evidence from the AWARE study in Germany highlights the need for greater awareness of guideline recommendations for the treatment of patients with H1-antihistamine-refractory chronic sponataneous urticaria. Poster PO93 DDG Berlin 2019.

Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019b;49(5):655-62

Maurer M, Staubach P, Raap U, et al. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol 2016;174(4):892–4

Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it‘s worse than we thought - first results of the multicenter real-life AWARE study. Clin Exp Allergy 2017d;47(5):684–92

Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011;66(3):317–30

Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15(3):253–60

Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014;150(3):288-90

Mlynek A, Magerl M, Hanna M, et al. The German version of the chronic urticaria quality-of-life questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009;64(6):927–36

Mlynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008;63(6):777–80

Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020;145(2):528-36.e1

Nayak AS, Berger WE, LaForce CF, et al. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc 2017;38(3):222–30

Novak Z, Yanez A, Kiss I, et al. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol 2016;27(5):493–8

Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and minimal important difference of the urticaria control test. J Allergy Clin Immunol 2017;10.1016/j.jaci.2017.04.050

Pampura AN, Papadopoulos NG, Spicak V, et al. Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. Int Arch Allergy Immunol 2011;155(4):367–78

Peteiro C, Toribio J. Incidence of leukocytoclastic vasculitis in chronic idiopathic urticaria. Study of 100 cases. Am J Dermatopathol 1989;11(6):528–33

Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol 2016;27(1):55–61

Radonjic-Hoesli S, Hofmeier KS, Micaletto S, et al. Urticaria and angioedema: an update on classification and pathogenesis. Clin Rev Allergy Immunol 2017;10.1007/s12016-017-8628-1

Rutkowski K, Grattan CEH. How to manage chronic urticaria ‘beyond’ guidelines: a practical algorithm. Clin Exp Allergy 2017;47(6):710–8

Sanclemente G, Burgos C, Nova J, et al. The impact of skin diseases on quality of life: A multicenter study. Actas Dermosifliogr 2017;108(3):244–52

Schielein MC, Tizek L, Seifert F, et al. Health care of chronic inflammatory skin diseases: Do affected individuals seek dermatological care? Hautarzt 2019;70(11):875-82

Schwarz EB, Moretti ME, Nayak S, et al. Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis. Drug Saf 2008;31(9):775–88

Shakouri A, Compalati E, Lang DM, et al. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol 2010;10(4):362–9

Sussman G, Hebert J, Gulliver W, et al. Omalizumab retreatment of patients with chronic idiopathic urticaria / chronic spontaneous urticaria following return of symptoms: Primary results of the optima study. Präsentation auf dem Jahreskongress der EAACI, Helsinki, Finnland, 17.-21.Juni 2017

Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006;55(4):705–9

Wagner N, Schielein M, Hacker E, et al. Patients with CU need better treatment: Results from the DERMLINE online survey. Posterbeitrag EADV 2019.P1958

Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008;26(1):19–23

Wedi B, Raap U, Kapp A. Chronic urticaria and infections. Curr Opin Allergy Clin Immunol 2004;4(5):387–96

Wedi B, Raap U, Wieczorek D, et al. Urticaria and infections. Allergy Asthma Clin Immunol 2009;5(1):10

Weller K, Ardelean E, Scholz E, et al. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol 2013a;93(2):168–74

Weller K, Donoso T, Magerl M, et al. Development of the Angioedema Control Test - a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy 2019;10.1111/all.14144

Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test (AECT) - a patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract 2020;10.1016/j.jaip.2020.02.038

Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014;133(5):1365-72, 72.e1-6

Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy 2012;67(10):1289–98

Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy 2013b;68(9):1185–92

Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy 2013c; 10.1111/all.12209

Weller K, Magerl M, Peveling-Oberhag A, et al. The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference. Allergy 2016;71(8):1203–9

Weller K, Siebenhaar F, Hawro T, et al. Clinical measures of chronic urticaria. Immunol Allergy Clin North Am 2017;37(1):35–49

Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria, the 2017 revision and update. Allergy 2018;73:1393–1414

Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64(10):1427–43

Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010;35(8):869–73

Zuberbier T, Chantraine-Hess S, Hartmann K, et al. Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study. Acta Derm Venereol 1995;75(6):484–7

Zuberbier T, Iffländer J, Semmler C, et al. Acute urticaria - clinical aspects and therapeutical responsiveness. Acta Derm Venereol 1996;76:295-7

Zuberbier T, Pfrommer C, Specht K, et al. Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria. J Allergy Clin Immunol 2002;109(2):343–8

Zuberbier T, Schadendorf D, Haas N, et al. Enhanced P-selectin expression in chronic and dermographic urticaria. Int Arch Allergy Immunol 1997;114(1):86–9